Efficacy and safety of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis

Submitted by Anonymous on

BackgroundAntibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine Abstract Background: Antibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor...

Cancer therapy-related cardiovascular toxicity observed during third-generation EGFR-TKI-based treatment in EGFR-mutant NSCLC: a retrospective cohort study

Submitted by Anonymous on

AbstractBackground Cardiovascular toxicity has been reported during treatment with osimertinib, but evidence for other third-generation EGFR tyrosine kinase inhibitors remains limited. Whether similar cardiovascular abnormalities occur during treatment with different agents in this class remains uncertain. We investigated the incidence,...

Imagenomix brings EGFR mutation prediction from routine H&E slides to Techcyte Fusion AP

Submitted by Anonymous on

Pulmogene-Predict lets pathologists explore molecular signals digitally in research and trial work without using additional tissue OREM, UT, UNITED STATES, October 13, 2026 / EINPresswire.com / -- Techcyte , developer of Fusion, the enterprise digital pathology platform, today announced that...

Prognostic significance of EGFR-1 and VEGF-A expression in feline cutaneous squamous cell carcinoma

Submitted by Anonymous on

IntroductionCutaneous squamous cell carcinoma (cSCC) is a prevalent malignancy in cats, and advanced cases remain challenging to manage due to their high pot 1 Introduction Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent skin tumors in cats,...

Ononin suppresses proliferation and glycolysis in hepatocellular carcinoma via the EGFR/PI3K/AKT signaling pathway

Submitted by Anonymous on

This study investigated the inhibitory effect of Ononin on hepatocellular carcinoma (HCC) and to elucidate its molecular mechanisms. CCK-8, EdU, colony formation, and Transwell assays were used to assess HCC cell proliferation, migration, and invasion. Western blotting and RT-qPCR analyzed...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer PR Newswire Mon, October 12,...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed to the next planned dose level of RC220 in combination with...

EGFR-TKI-associated colitis in non-small cell lung cancer: a retrospective characterization of clinical, radiographic, endoscopic, and histopathologic features

Submitted by Anonymous on

ObjectiveEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard targeted therapies for EGFR-mutant non-small cell lung cancer ( Abstract Objective: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard targeted therapies for EGFR-mutant non-small cell lung cancer (NSCLC),...

Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety

Submitted by Anonymous on

ObjectiveFor advanced EGFR-mutant non-small cell lung cancer (NSCLC), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) therapy is the p Abstract Objective: For advanced EGFR-mutant non-small cell lung cancer (NSCLC), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) therapy is...

Subscribe to Newsfeed